In a first-of-its-kind study, researchers show that vaginal estrogen is safe for treatment of genitourinary syndrome of menopause (GSM) in survivors of gynecologic cancer. Gynecologic oncologist Stephanie Ricci, MD, explains how the treatment may safely improve quality of life for select patients.
Laser and estrogen therapies are similarly effective treatments for genitourinary syndrome of menopause, according to a recently published, multi-institutional trial. Gynecologist and principal investigator Marie Fidela Paraiso, MD, discusses the trial and the setbacks the team has encountered, despite the positive results.
Managing patients who develop genitourinary syndrome of menopause while on endocrine therapy for breast cancer can be complex. In this article, Cleveland Clinic specialists discuss their proactive, comprehensive approach, including the latest nonhormonal and local therapies.
Three forms of treatment refractory chronic vaginitis to consider: atrophic vaginitis, desquamative inflammatory vaginitis and genital graft vs. host disease
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Women’s health experts explain the options for patients who need hormonal therapy for GSM, including locally applied estrogens and estrogen receptor agonists/antagonists, which vary in their impact on breast cancer risk.